story of the week
Overall Survival With Sacituzumab Govitecan in Patients With Pretreated, Endocrine-Resistant, HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
Lancet 2023 Aug 23;[EPub Ahead of Print], HS Rugo, A Bardia, F Marmé, J Cortés, P Schmid, D Loirat, O Trédan, E Ciruelos, F Dalenc, P Gómez Pardo, KL Jhaveri, R Delaney, T Valdez, H Wang, M Motwani, OK Yoon, W Verret, SM TolaneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.